Ask about this productRelated genes to: C11ORF65 Blocking Peptide
- Gene:
- C11orf65 NIH gene
- Name:
- chromosome 11 open reading frame 65
- Previous symbol:
- -
- Synonyms:
- MGC33948
- Chromosome:
- 11q22.3
- Locus Type:
- gene with protein product
- Date approved:
- 2006-03-10
- Date modifiied:
- 2017-08-07
Related products to: C11ORF65 Blocking Peptide
Related articles to: C11ORF65 Blocking Peptide
- Compared to European American women, African American women are more likely to be diagnosed with triple-negative breast cancer (TNBC). This difference may be partially due to genetic factors. This study aims to investigate associations of African ancestry and risk variants with TNBC among African American women. - Source: PubMed
Publication date: 2026/05/07
Jia GuochongLiu LiliPing JieFiorica Peter NGuo XingyiTao RanLi BingshanGu JianJohn Esther MOlopade Olufunmilayo IPress Michael FBrewster Abenaa MOlshan Andrew FZirpoli GaryButler Ebonee NHuang MaoshengHuo DezhengPalmer Julie RHaiman Christopher AAmbrosone Christine BTroester Melissa ALong JirongYao SongZheng Wei - Telomeres are important for maintaining genomic stability. Telomere length has been associated with aging, disease, and mortality and is highly heritable (∼82%). In this study, we aimed to identify rare genetic variants associated with telomere length using whole-exome sequence data. We studied 1,303 participants of the Erasmus Rucphen Family (ERF) study, 1,259 of the Rotterdam Study (RS), and 674 of the British Heart Foundation Family Heart Study (BHF-FHS). We conducted two analyses, first we analyzed the family-based ERF study and used the RS and BHF-FHS for replication. Second, we combined the summary data of the three studies in a meta-analysis. Telomere length was measured by quantitative polymerase chain reaction in blood. We identified nine rare variants significantly associated with telomere length (-value < 1.42 × 10, minor allele frequency of 0.2-0.5%) in the ERF study. Eight of these variants (in , , , , , and ) were located on chromosome 11q22.3 that contains , a gene involved in telomere maintenance. Although we were unable to replicate the variants in the RS and BHF-FHS (-value ≥ 0.21), segregation analysis showed that all variants segregate with shorter telomere length in a family. In the meta-analysis of all studies, a nominally significant association with LTL was observed with a rare variant in (- = 1.48 × 10), which has previously been associated with age. Additionally, a novel rare variant in the known locus showed suggestive evidence for association (-value = 1.18 × 10) with LTL. To conclude, we identified novel rare variants associated with telomere length. Larger samples size are needed to confirm these findings and to identify additional variants. - Source: PubMed
Publication date: 2020/04/30
van der Spek AshleyWarner Sophie CBroer LindaNelson Christopher PVojinovic DinaAhmad ShahzadArp Pascal PBrouwer Rutger W WDenniff Matthewvan den Hout Mirjam C G Nvan Rooij Jeroen G JKraaij Robertvan IJcken Wilfred F JSamani Nilesh JIkram M ArfanUitterlinden André GCodd VeryanAmin Najafvan Duijn Cornelia M - Identification of high-risk stage II colorectal cancer (CRC) patients, potential candidates for adjuvant chemotherapy, is challenging. Current clinical guidelines rely mainly on histopathological markers with relatively weak prognostic value. This motivates further search for prognostic markers. - Source: PubMed
Publication date: 2020/05/14
Dimberg JanAndersson Roland EHaglund Sofie - In Mexico, approximately 25% of patients with type 2 diabetes (T2D) have adequate glycemic control. Polymorphisms in pharmacogenetic genes have been shown to have clinical consequences resulting in drug toxicity or therapeutic inefficacy. - Source: PubMed
Marta MenjivarSánchez-Pozos KatyJaimes-Santoyo JoelMonroy-Escutia JazminRivera-Santiago Carolinade Los Ángeles Granados-Silvestre MaríaOrtiz-López María Guadalupe - There is variation in the responsiveness of locally advanced rectal cancer to neoadjuvant chemoradiation, from complete response to total resistance. This study compared genetic variation in rectal cancer patients who had a complete response to chemoradiation versus poor response, using tumor tissue samples sequenced with genomics analysis software. Rectal cancer patients treated with chemoradiation and proctectomy June 2006-March 2017 were grouped based on response to chemoradiation: those with no residual tumor after surgery (CR, complete responders, AJCC-CPR tumor grade 0, n = 8), and those with poor response (PR, AJCC-CPR tumor grade two or three on surgical resection, n = 8). We identified 195 variants in 83 genes in tissue specimens implicated in colorectal cancer biopathways. PR patients showed mutations in four genes not mutated in complete responders: KDM6A, ABL1, DAXX-ZBTB22, and KRAS. Ten genes were mutated only in the CR group, including ARID1A, PMS2, JAK1, CREBBP, MTOR, RB1, PRKAR1A, FBXW7, ATM C11orf65, and KMT2D, with specific discriminating variants noted in DMNT3A, KDM6A, MTOR, APC, and TP53. Although conclusions may be limited by small sample size in this pilot study, we identified multiple genetic variations in tumor DNA from rectal cancer patients who are poor responders to neoadjuvant chemoradiation, compared to complete responders. - Source: PubMed
Publication date: 2020/03/02
Douglas Jason KCallahan Rose EHothem Zachary ACousineau Craig SKawak SamerThibodeau Bryan JBergeron ShelliLi WeiPeeples Claire EWasvary Harry J